“As good as we saw results in 1 month, we think we'll see even more remarkable results over the 6 months of treatment,” Edelson said in an interview with Dermatology Times.
Jon Edelson, MD
Advertisement
Jon Edelson, MD, is the Chairman, CEO, and President of Eirion Therapeutics
Articles by Jon Edelson, MD
Jon Edelson, MD, CEO of Eirion, confirms that topical ET-02 is a completely new approach to treating this type of hair loss.
Advertisement
Latest Updated Articles
What’s Next for ET-02? CEO of Eirion, Jon Edelson, MD, Shares Phase 2 PlansPublished: January 14th 2025 | Updated:
The Unprecedented Phase 1 Results of ET-02 for the Treatment of Androgenic AlopeciaPublished: January 14th 2025 | Updated:
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
3
Reviewing Type 2 Inflammation Through a Different Lens
4
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
5
